Edwards Lifesciences Corporation — FY 2017 Form 10-K
Reporting period: Fiscal year ended December 31, 2017. The filing is an annual report, not a standalone fourth-quarter filing. Edwards develops and sells structural-heart therapies and critical-care monitoring products worldwide.
Financial performance and position
| Metric | FY 2017 | FY 2016 | Change |
|---|---|---|---|
| Net sales | $3.435 billion | $2.964 billion | +15.9% |
| Gross profit | $2.560 billion | $2.166 billion | +18.2% |
| Gross margin | 74.5% | 73.1% | +1.4 percentage points |
| Net income | $583.6 million | $569.5 million | +2.5% |
| Diluted EPS | $2.70 | $2.61 | +3.4% |
| Operating cash flow | $1.001 billion | $704.4 million | +$296.3 million |
- Revenue mix: Transcatheter Heart Valve Therapy (THVT) sales rose 24.5% to $2.027 billion and represented 59% of sales. Surgical Heart Valve Therapy sales increased 4.2% to $807.1 million; Critical Care sales increased 7.3% to $601.0 million.
- Costs and investment: R&D expense was $552.6 million, up from $442.2 million; management cited development work in mitral, aortic, and tricuspid therapies. SG&A expense was $984.7 million, versus $904.7 million.
- Cash and liquidity: Cash and cash equivalents were $818.3 million; short- and long-term investments totaled $1.086 billion. Current assets were $2.532 billion and current liabilities $1.403 billion. Management said available liquidity and operating cash flows should fund working capital, capital expenditures, and other commitments for the next 12 months.
- Debt: Year-end debt carrying value was approximately $1.036 billion: $598.0 million of senior notes classified as short-term and $438.4 million outstanding under the credit agreement, classified as long-term. The $600 million 2.875% notes mature in October 2018; the company said it planned to issue new notes to partially replace them. Credit-facility covenants were met.
- Capital allocation: The company repurchased 7.7 million shares for $763.3 million during 2017 and had $1.3 billion of repurchase authorization remaining at year-end. It has no current plan to pay cash dividends.
Changes versus the prior year
- Sales growth moderated to 15.9% from 18.8% in 2016. THVT remained the principal growth driver, supported by SAPIEN 3 adoption in the United States, Japan, and Europe.
- Gross margin improved, mainly from a more favorable product mix led by THVT; Hurricane Maria-related costs in Puerto Rico and the planned Swiss plant closure partly offset the improvement.
- Net income rose only modestly despite higher sales. The 2017 tax provision was $451.3 million, versus $168.4 million in 2016, reflecting tax-law changes; the filing identifies a $262 million tax expense related to U.S. tax-law implementation in fourth-quarter results.
- Operating cash flow rose to $1.001 billion, reflecting improved operating performance and a litigation receipt, partly offset by higher working-capital needs and tax-payment timing. Investing outflows increased to $647.2 million, including acquisitions and capital spending.
Outlook, commentary, risks, and unusual items
- Outlook: The filing provides no clear numerical forward revenue or earnings guidance. Management emphasized continued investment in structural-heart innovation and clinical evidence, and stated that liquidity was sufficient for near-term requirements.
- Product and acquisition developments: Edwards acquired Valtech, developer of mitral and tricuspid repair technologies, and Harpoon Medical, focused on beating-heart mitral repair. FDA approvals included HemoSphere, SAPIEN 3 valve-in-valve procedures, and INSPIRIS RESILIA. Harpoon received CE Mark. These programs remain subject to development, clinical, and regulatory risks.
- Tax transition: The 2017 tax law generated a provisional $327.4 million mandatory repatriation tax obligation, with a provisional net tax-expense impact of $297.4 million after related tax-position effects. The company intended to pay in installments over eight years; the estimates remained subject to adjustment.
- Litigation and other unusual items: Edwards recorded a $112.5 million litigation gain in November related to alleged trade-secret theft. Special charges included a $25.0 million foundation contribution, $31.2 million investment-related impairment, and $10.2 million of Swiss plant-closure and realignment costs. Separately, Boston Scientific patent litigation includes adverse German and U.K. rulings involving SAPIEN 3; appeals and other proceedings were ongoing, and injunctions or damages could affect sales or results.
- Key risks: Regulatory approval delays and changing medical-device rules; clinical-trial and product-development uncertainty; reimbursement and pricing pressure; competition and product obsolescence; supply and manufacturing disruptions; foreign-exchange exposure; product-liability and intellectual-property litigation; cybersecurity; and unresolved tax and transfer-pricing matters. The company also cited costs from Hurricane Maria and the planned closure of its Swiss manufacturing plant.
Important facts for investors to verify
- Whether THVT growth and SAPIEN 3 adoption continue, and whether surgical-valve sales withstand substitution toward transcatheter procedures.
- The final tax effects of the 2017 tax law, installment payments, and outcomes of IRS transfer-pricing and other uncertain-tax matters.
- Refinancing or repayment of the $600 million notes due in October 2018, alongside credit-facility obligations and planned repurchases.
- Developments in Boston Scientific patent disputes, including appeals, potential injunctions, damages, and the effect on SAPIEN 3 sales.
- Progress, regulatory milestones, and contingent-payment exposure for Valtech and Harpoon; the filing estimates contingent payments could total up to approximately $680 million if applicable milestones are achieved.
- Recovery of Puerto Rico manufacturing operations after Hurricane Maria, execution of the Swiss closure, and any resulting costs or supply impacts.